bioLytical® Laboratories is persistently innovative in improving existing products and also in bringing new high-performance products to market. Our pipeline is continually growing to honor our commitment in deploying the INSTI® platform to disease states where significant unmet public health needs intersect with commercial opportunity.
The INSTI® platform uses innovative flow-through technology to provide point-of-care diagnostic tests which are both fast and highly accurate. Competing rapid test platforms utilize lateral flow technology but the speed-to-result is inherently constrained by such technology. For example, the INSTI® platform adapted to HIV resulted in a highly accurate HIV antibody test that provides a result in 60 seconds or less, far faster than the 15-20 minutes required for tests based on lateral flow technology. The speed of INSTI® generates meaningful clinical and financial advantages that translate into a compelling value proposition for patients, healthcare professionals, payers and public health organizations.
The INSTI® platform is highly adaptable to a wide range of infectious and other diseases. bioLytical® Laboratories is committed to expanding its product lines by deploying the INSTI® platform to disease states where significant unmet public health needs intersect with commercial opportunity. Our R&D team is focused on advancing our product pipeline and also provides contract development services for novel applications of the INSTI® platform.
bioLytical® Laboratories Development Services teams provide contract services to adapt the INSTI® platform to meet custom functional and technical diagnostic testing requirements.
Key benefits of working with our Development Services teams: